Actinium

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company based in Florham Park, NJ, specializing in the development of targeted radiotherapies for patients with unmet medical needs. With a pipeline of Antibody Radiation Conjugates, the company focuses on targeted conditioning and combination therapies, aiming to provide innovative solutions for various diseases.

Actinium Pharmaceuticals has achieved significant milestones, including positive top-line results from the pivotal Phase 3 SIERRA Trial for Iomab-B, which met its primary endpoint. The company's commitment to targeted conditioning and targeted radiotherapy is evident in its development of CD33 targeting Actimab-A and Iomab-ACT for gene cell therapy conditioning, offering potential therapeutic options for patients with acute myeloid leukemia and other conditions.

Generated from the website